Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Shin-ya Tamechika"'
Autor:
Hiroya Hashimoto, Akio Niimi, Shinji Maeda, Tomoyo Maeda, Shin-ya Tamechika, Shuntaro Isogai, Taio Naniwa
Publikováno v:
Lupus Science and Medicine, Vol 10, Iss 2 (2023)
Objective This study sought to elucidate the molecular impacts of belimumab (BEL) treatment on T-cell immune profiling in SLE.Methods We used mass cytometry with 25 marker panels for T-cell immune profiling in peripheral blood T cells (CD3+) from 22
Externí odkaz:
https://doaj.org/article/612360ce96a44cc9887109b7f49f5bd0
Autor:
Natsuo Tomita, MD, PhD, Shin-Ya Tamechika, MD, PhD, Daisuke Kawakita, MD, PhD, Kenta Saito, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 4, Pp 100695- (2021)
Externí odkaz:
https://doaj.org/article/84bdf76114c44f3ebdbee14697840658
Publikováno v:
Case Reports in Rheumatology, Vol 2021 (2021)
A case of eosinophilic granulomatosis with polyangiitis (EGPA) in which chronic rhinosinusitis (CRS) was improved with a reduction in the myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) titer after the addition of mepolizumab is report
Externí odkaz:
https://doaj.org/article/39bbc9b0215f452da0f0267208dbc9b3
Autor:
Shinji Maeda, Satoshi Osaga, Tomoyo Maeda, Norihisa Takeda, Shin-Ya Tamechika, Taio Naniwa, Akio Niimi
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0215192 (2019)
T-helper (Th)17.1 cells exhibit high pathogenicity in inflammatory diseases. This study aimed to identify the changes in the proportions of Th subsets, including Th17.1, which are associated with abatacept treatment response in Japanese patients with
Externí odkaz:
https://doaj.org/article/6d550e74b8044b19972ed30aaf51d37c
Publikováno v:
Journal of Bone and Mineral Metabolism. 41:203-211
Evidence on second-line agents for osteoporosis and osteopenia associated with glucocorticoid use after first-line bisphosphonate therapy is limited. We, therefore, examine the efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707e33b6320e023dbb16a864e561fe83
https://doi.org/10.1007/s00774-022-01393-9
https://doi.org/10.1007/s00774-022-01393-9
Autor:
Taio Naniwa, Toru Yamabe, Shin‐ichiro Ohmura, Koji Uehara, Shin‐ya Tamechika, Shinji Maeda, Shuntaro Isogai, Junichi Wada
Publikováno v:
International Journal of Rheumatic Diseases. 25:1003-1012
Macrophage activation syndrome (MAS), a severe complication of systemic adult-onset Still's disease (AOSD), has been reported to occur during interleukin-6 (IL-6) inhibitor treatment. However, predictors for MAS development are unknown. Therefore, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a19d6f3bd9426cb519c5dbf7b598b73
https://doi.org/10.1111/1756-185x.14371
https://doi.org/10.1111/1756-185x.14371
Publikováno v:
International Journal of Rheumatic Diseases. 25:897-909
To investigate the impact of dysphagia on long-term survival and swallowing function outcomes in patients with idiopathic inflammatory myopathy other than inclusion body myositis.We retrospectively evaluated consecutive patients with idiopathic infla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b267a6178b975f37a5b65e2b2a4e5845
https://doi.org/10.1111/1756-185x.14365
https://doi.org/10.1111/1756-185x.14365
Autor:
Shinji Maeda, Hiroya Hashimoto, Tomoyo Maeda, Shin-ya Tamechika, Shuntaro Isogai, Taio Naniwa, Akio Niimi
Publikováno v:
Lupus Science & Medicine; 2023, Vol. 10 Issue 2, p1-12, 12p